Characterization of diabetic nephropathy by urinary proteomic analysis: Identification of a processed ubiquitin form as a differentially excreted protein in diabetic nephropathy patients

Clinical Chemistry

Volumn 53, Issue 9, 2007, Pages 1636-1645

  Dihazi, Hassan ^a,c   Müller, Gerhard A ^a   Lindner, Sandra ^a   Meyer, Markus ^b   Asif, Abdul R ^a   Oellerich, Michael ^a   Strutz, Frank ^a  

^a UNIVERSITY MEDICAL CENTER GÖTTINGEN   (Germany)

^b ISRAELITISCHES KRANKENHAUS   (Germany)

^c UNIVERSITY OF GÖTTINGEN   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

PROTEIN; UBIQUITIN;

AGED; ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; DIABETIC NEUROPATHY; DIABETIC PATIENT; FEMALE; GEL ELECTROPHORESIS; HUMAN; KIDNEY DISEASE; MALE; MASS SPECTROMETRY; MICROALBUMINURIA; PROTEIN ANALYSIS; PROTEIN PURIFICATION; PROTEINURIA; PROTEOMICS; SURFACE ENHANCED LASER DESORPTION IONIZATION TIME OF FLIGHT MASS SPECTROMETRY; URINALYSIS;

AGED; ALBUMINURIA; BIOLOGICAL MARKERS; DIABETIC NEPHROPATHIES; FEMALE; HUMANS; MALE; MIDDLE AGED; PROTEIN ARRAY ANALYSIS; PROTEOME; REPRODUCIBILITY OF RESULTS; SPECTROMETRY, MASS, MATRIX-ASSISTED LASER DESORPTION-IONIZATION; UBIQUITINS;

EID: 34548363484     PISSN: 00099147     EISSN: None     Source Type: Journal    
DOI: 10.1373/clinchem.2007.088260     Document Type: Article

References (40)

1. Mokdad AH, Ford ES, Bowman BA, Dietz WH, Vinicor F, Bales VS, et al. Prevalence of obesity, diabetes, and obesity-related health risk factors, 2001. JAMA 2003;289:76-9.
2. Janka HU. Increased cardiovascular morbidity and mortality in diabetes mellitus: identification of the high risk patient. Diabetes Res Clin Pract 1996;30(Suppl):85-8.
3. Ritz E, Dikow R. Hypertension and antihypertensive treatment of diabetic nephropathy. Nat Clin Pract Nephrol 2006;2:562-7.
4. Fioretto P, Bruseghin M, Berto I, Gallina P, Manzato E, Mussap M. Renal protection in diabetes: role of glycemic control. J Am Soc Nephrol 2006;17:S86-9.
5. Remuzzi G, Schieppati A, Ruggenenti P. Clinical practice. Nephropathy in patients with type 2 diabetes. N Engl J Med 2002;346:1145-51.
6. Mykkanen L, Haffner SM, Kuusisto J, Pyorala K, Laakso M. Microalbuminuria precedes the development of NIDDM. Diabetes 1994;43:552-7.
7. Dihazi H. Clinical proteomics: an insight into the urinary proteome: interview with Dr. Hassan Dihazi. Expert Rev Proteomics 2006;3:481-2.
8. Dihazi H, Muller GA. Urinary proteomics: a tool to discover biomarkers of kidney diseases. Expert Rev Proteomics 2007;4:39-50.
9. Muller GA, Muller CA, Dihazi H. Clinical proteomics: on the long way from bench to bedside? Nephrol Dial Transplant 2007;22:1297-300.
10. Wilkins MR, Appel RD, Van Eyk JE, Chung MC, Gorg A, Hecker M, et al. Guidelines for the next 10 years of proteomics. Proteomics 2006;6:4-8.
11. Bradford MM. A rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of protein-dye binding. Anal Biochem 1976;72:248-54.
12. Shevchenko A, Wilm M, Vorm O, Mann M. Mass spectrometric sequencing of proteins silver-stained polyacrylamide gels. Anal Chem 1996;68:850-8.
13. Dihazi H, Müller C, Asif A, Flad T, Elmaouhoub A, Müller G. Whole cell profiling and identification of galectin-1 as a potential marker of renal cell carcinoma. Proteomics Clinical Applications 2007;1:200-14.
14. Dihazi H, Asif AR, Agarwal NK, Doncheva Y, Muller GA. Proteomic analysis of cellular response to osmotic stress in thick ascending limb of Henle's loop (TALH) cells. Mol Cell Proteomics 2005;4:1445-58.
15. Tolson JP, Flad T, Gnau V, Dihazi H, Hennenlotter J, Beck A, et al. Differential detection of S100A8 in transitional cell carcinoma of the bladder by pair wise tissue proteomic and immunohistochemical analysis. Proteomics 2006;6:697-708.
16. Towbin H, Staehelin T, Gordon J. Electrophoretic transfer of proteins from polyacrylamide gels to nitrocellulose sheets: procedure and some applications: 1979. Biotechnology 1992;24:145-9.
17. de Bont JM, den Boer ML, Reddingius RE, Jansen J, Passier M, van Schaik RH, et al. Identification of apolipoprotein A-II in cerebrospinal fluid of pediatric brain tumor patients by protein expression profiling. Clin Chem 2006;52:1501-9.
18. Molitch ME, DeFronzo RA, Franz MJ, Keane WF, Mogensen CE, Parving HH. Diabetic nephropathy. Diabetes Care 2003;26(Suppl 1):S94-8.
19. Decramer S, Wittke S, Mischak H, Zurbig P, Walden M, Bouissou F, et al. Predicting the clinical outcome of congenital unilateral ureteropelvic junction obstruction in newborn by urinary proteome analysis. Nat Med 2006;12:398-400.
20. Schaub S, Wilkins J, Weiler T, Sangster K, Rush D, Nickerson P. Urine protein profiling with surface-enhanced laser-desorption/ionization time-of-flight mass spectrometry. Kidney Int 2004;65:323-32.
21. Clarke W, Silverman BC, Zhang Z, Chan DW, Klein AS, Molmenti EP. Characterization of renal allograft rejection by urinary proteomic analysis. Ann Surg 2003;237:660-4.
22. Li J, Zhang Z, Rosenzweig J, Wang YY, Chan DW. Proteomics and bioinformatics approaches for identification of serum biomarkers to detect breast cancer. Clin Chem 2002;48:1296-304.
23. Schaub S, Wilkins JA, Antonovici M, Krokhin O, Weiler T, Rush D, et al. Proteomic-based identification of cleaved urinary beta2-microglobulin as a potential marker for acute tubular injury in renal allografts. Am J Transplant 2005;5:729-38.
24. Thongboonkerd V, Barati MT, McLeish KR, Pierce WM, Epstein PN, Klein JB. Proteomics and diabetic nephropathy. Contrib Nephrol 2004;141:142-54.
25. Thongboonkerd V, Malasit P. Renal and urinary proteomics: current applications and challenges. Proteomics 2005;5:1033-42.
26. Susztak K, Bottinger EP. Diabetic nephropathy: a frontier for personalized medicine. J Am Soc Nephrol 2006;17:361-7.
27. Hong CY, Hughes K, Chia KS, Ng V, Ling SL Urinary alpha1-microglobulin as a marker of nephropathy in type 2 diabetic Asian subjects in Singapore. Diabetes Care 2003;26:338-42.
28. Rossing K, Mischak H, Parving HH, Christensen PK, Walden M, Hillmann M, et al. Impact of diabetic nephropathy and angiotensin II receptor blockade on urinary polypeptide patterns. Kidney Int 2005;68:193-205.
29. Schaub S, Rush D, Wilkins J, Gibson IW, Weiler T, Sangster K, et al. Proteomic-based detection of urine proteins associated with acute renal allograft rejection. J Am Soc Nephrol 2004;15:219-27.
30. O'Riordan E, Orlova TN, Mei JJ, Butt K, Chander PM, Rahman S, et al. Bioinformatic analysis of the urine proteome of acute allograft rejection. J Am Soc Nephrol 2004;15:3240-8.
31. Petricoin EF, Ardekani AM, Hitt BA, Levine PJ, Fusaro VA, Steinberg SM, et al. Use of proteomic patterns in serum to identify ovarian cancer. Lancet 2002;359:572-7.
32. Schardijn G, Statius van Eps LW, Swaak AJ, Kager JC, Persijn JP. Urinary beta 2 microglobulin in upper and lower urinary-tract infections. Lancet 1979;1:805-7.
33. Schardijn GH, Statius van Eps LW. Beta 2-microglobulin: its significance in the evaluation of renal function. Kidney Int 1987;32:635-41.
34. Hong CY, Chia KS. Markers of diabetic nephropathy. J Diabetes Complications 1998;12:43-60.
35. Hershko A, Ciechanover A. The ubiquitin system. Annu Rev Biochem 1998;67:425-79.
36. Sun L, Pan X, Wada J, Haas CS, Wuthrich RP, Danesh FR, et al. Isolation and functional analysis of mouse UbA52 gene and its relevance to diabetic nephropathy. J Biol Chem 2002;277:29953-62.
37. Brownlee M. Biochemistry and molecular cell biology of diabetic complications. Nature 2001;414:813-20.
38. Glickman MH, Ciechanover A. The ubiquitin-proteasome proteolytic pathway: destruction for the sake of construction. Physiol Rev 2002;82:373-428.
39. Wilkinson KD. Ubiquitination and deublquitination: targeting of proteins for degradation by the proteasome. Semin Cell Dev Biol 2000;11:141-8.
40. Wing SS. Deubiquitinating enzymes: the importance of driving in reverse along the ubiquitin-proteasome pathway. Int J Biochem Cell Biol 2003;35:590-605.